Sec­ond dose of Sophiris' prostate can­cer drug proves fu­tile, shares crash

Fol­low­ing a pa­tient death that was ruled un­re­lat­ed to the study drug, Sophiris Bio con­tin­ued test­ing a sec­ond ad­min­is­tra­tion of its ex­per­i­men­tal drug in pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER